These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 13691408)

  • 1. [Control of the antigenic power of vaccine for poliomyelitis prepared with inactivated virus].
    CASTELLI L; BALDUCCI D; MANCINI G; PAULUZZI S
    Riv Ist Sieroter Ital; 1960; 35():529-38. PubMed ID: 13691408
    [No Abstract]   [Full Text] [Related]  

  • 2. [First results of human antipoliomyelitis vaccination with vaccine prepared with the Salk type of inactivated virus].
    SANTOPADRE G
    Nuovi Ann Ig Microbiol; 1959; 10():359-61. PubMed ID: 14441610
    [No Abstract]   [Full Text] [Related]  

  • 3. [Inhibition of neutralizing power of anti-poliomyelitis serum and action of inactivated virus].
    INSERILLO G; ODDO FG
    Riv Ist Sieroter Ital; 1956; 31(3):185-6. PubMed ID: 13380265
    [No Abstract]   [Full Text] [Related]  

  • 4. [Remarks on methods used for the control of the antigenic power of lots of inactivated antipolio-myelitis vaccine. Comparative study of 3 survey environments].
    CELERS J; LAZAR P; DROUHET V; BOUE A; ZOURBAS J; SAID G; DRAI M
    Rev Fr Etud Clin Biol; 1962 Mar; 7():260-70. PubMed ID: 13877625
    [No Abstract]   [Full Text] [Related]  

  • 5. Studies on poliomyelitis virus. II. The immunogenic potency of live and inactivated virus in guinea-pigs.
    HAMPTON JW; POLSON A; SELZER G
    J Hyg (Lond); 1958 Jun; 56(2):260-5. PubMed ID: 13563867
    [No Abstract]   [Full Text] [Related]  

  • 6. Neutralizing-antibody-combining (NAC) test for measuring antigenic potency of poliomyelitis vaccine.
    BENYESH-MELNICK M; MELNICK JL
    Bull World Health Organ; 1959; 20(6):1075-98. PubMed ID: 13799058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Complement fixing antibodies after vaccination with inactivated polio virus].
    LENNARTZ H; HERTENSTEIN C; CRUESEMANN R
    Klin Wochenschr; 1959 Dec; 37():1261-2. PubMed ID: 14415702
    [No Abstract]   [Full Text] [Related]  

  • 8. The determination of antigenic potency of poliomyelitis vaccine by measuring its antibody-combining capacity.
    KRECH U
    Bull World Health Organ; 1960; 22(3-4):307-11. PubMed ID: 14411872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [On the in vitro titration of the antigenic power of vaccines against poliomyelitis].
    PETRILLI FL; AGNESE G; CROVARI P
    Boll Ist Sieroter Milan; 1960; 39():168-88. PubMed ID: 14432312
    [No Abstract]   [Full Text] [Related]  

  • 10. [A vaccine against poliomyelitis--its production and requirements (live and killed vaccines)].
    GAON J
    Med Arh; 1960; 14():1-9. PubMed ID: 13826342
    [No Abstract]   [Full Text] [Related]  

  • 11. [On the efficacy and harmlessness of vaccines from inactivated and attenuated poliomyelitis virus].
    AUERSWALD W
    Wien Klin Wochenschr; 1959 Dec; 71():965-7. PubMed ID: 13795088
    [No Abstract]   [Full Text] [Related]  

  • 12. [Determination of the antigenic value of poliomyelitis vaccine].
    DE SOMER P; PRINZIE A; DE MAEYER E; LAMY M
    Bull World Health Organ; 1960; 22(3-4):295-305. PubMed ID: 13815062
    [No Abstract]   [Full Text] [Related]  

  • 13. [A comparative study of the dynamics of inactivation of the virus in dialyzed and nondialyzed speciments of formalin-treated vaccine against poliomyelitis].
    DZAGUROV SG; SHMELEVA GA; VIL'NER LM
    Vopr Virusol; 1961; 6():616-7. PubMed ID: 13888871
    [No Abstract]   [Full Text] [Related]  

  • 14. Antigenic potency of poliomyelitis vaccine; influence on degree and duration of vaccine effect.
    SALK JE
    J Am Med Assoc; 1956 Dec; 162(16):1451-9. PubMed ID: 13376316
    [No Abstract]   [Full Text] [Related]  

  • 15. REQUIREMENTS for biological substances. 1. General requirements for manufacturing establishments and control laboratories. 2. Requirements for poliomyelitis vaccine (inactivated). Report of a study group.
    World Health Organ Tech Rep Ser; 1959; 178():1-30. PubMed ID: 13858460
    [No Abstract]   [Full Text] [Related]  

  • 16. SAFETY and antigenic potency testing of poliomyelitis vaccine; a report from the Biological Standards Control Laboratory, Medical Research Council Laboratories, London, N.W.3.
    Br Med J; 1957 Jul; 2(5037):124-6. PubMed ID: 13436874
    [No Abstract]   [Full Text] [Related]  

  • 17. [Inactivated or living virus in present poliomyelitis vaccination].
    CRAMER R
    Schweiz Med Wochenschr; 1956 Feb; 86(8):191-6. PubMed ID: 13311449
    [No Abstract]   [Full Text] [Related]  

  • 18. [Killed vaccine or live vaccine against poliomyelitis?].
    TOBIN JO
    Rev Immunol Ther Antimicrob; 1960; 24():195-201. PubMed ID: 13838591
    [No Abstract]   [Full Text] [Related]  

  • 19. [Antigenic studies on the French antipoliomyelitis vaccine].
    LEPINE P
    Ann Inst Pasteur (Paris); 1959 Dec; 97():780-93. PubMed ID: 14415884
    [No Abstract]   [Full Text] [Related]  

  • 20. [Study of the antigenicity of inactivated antipolimyelitis vaccine in a group of children in Bucharest].
    MARCOVICI M; BUIMOVICI E; CALOMFIRESCO A
    Arch Roum Pathol Exp Microbiol; 1961 Dec; 20():747-53. PubMed ID: 14469690
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.